At a glance
- Originator Roche Palo Alto LLC
- Class Anxiolytics; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 05 Sep 2001 No-Development-Reported for Anxiety disorders in USA (Unknown route)